Compare
Palatin Technologies Inc vs Bristol Myers Squibb Co vs TherapeuticsMD, Inc. vs Pfizer Inc
| Latest fiscal year | Palatin Technologies Inc PTN | Bristol Myers Squibb Co BMY | TherapeuticsMD, Inc. TXMD | Pfizer Inc PFE |
|---|---|---|---|---|
| Year ended | 2025-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $0 | $48.19B | $3.02M | $62.58B |
| Revenue growth (YoY) | -100.0% | -0.2% | +71.6% | -1.6% |
| Gross margin | n/a | n/a | n/a | 74.3% (computed) |
| Operating margin | n/a | n/a | -145.3% | n/a |
| Net margin | n/a | 14.6% | -18.8% | 12.4% |
| Net income | -$17.31M | $7.05B | -$569.0K | $7.77B |
| EPS (Diluted) | -$32.15 | $3.46 | -$0.05 | $1.36 |
| Operating cash flow | -$21.31M | $14.16B | $2.45M | $11.70B |
| Free cash flow | -$21.31M | $12.85B | n/a | $9.07B |
| Cash & equivalents | $2.56M | $10.21B | n/a | $1.14B |
| Total assets | $3.27M | $90.04B | $37.66M | $208.16B |
| Total liabilities | $8.04M | $71.53B | $10.78M | $121.39B |
| Shareholders' equity | -$4.78M | $18.47B | $26.88M | $86.78B |
| Return on year-end equity | n/a | 38.2% | -2.1% | 9.0% |
| Shares outstanding | 929.6K | n/a | 11.57M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Palatin Technologies Inc | Bristol Myers Squibb Co | TherapeuticsMD, Inc. | Pfizer Inc |
|---|---|---|---|---|
| Latest | $0 Ended 2025-06-30 | $48.19B Ended 2025-12-31 | $3.02M Ended 2025-12-31 | $62.58B Ended 2025-12-31 |
| 1 year earlier | $4.49M Ended 2024-06-30 | $48.30B Ended 2024-12-31 | $1.76M Ended 2024-12-31 | $63.63B Ended 2024-12-31 |
| 2 years earlier | $4.85M Ended 2023-06-30 | $45.01B Ended 2023-12-31 | $1.30M Ended 2023-12-31 | $59.55B Ended 2023-12-31 |
| 3 years earlier | $1.47M Ended 2022-06-30 | $46.16B Ended 2022-12-31 | $69.96M Ended 2022-12-31 | $101.17B Ended 2022-12-31 |
| 4 years earlier | -$188.6K Ended 2021-06-30 | $46.38B Ended 2021-12-31 | $2.57M Ended 2021-12-31 | $81.29B Ended 2021-12-31 |